296 related articles for article (PubMed ID: 25862591)
41. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
42. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.
Chhabra S; Ahn KW; Hu ZH; Jain S; Assal A; Cerny J; Copelan EA; Daly A; DeFilipp Z; Gadalla SM; Gale RP; Ganguly S; Hamilton BK; Hildebrandt GC; Hsu JW; Inamoto Y; Kanate AS; Khoury HJ; Lazarus HM; Litzow MR; Nathan S; Olsson RF; Pawarode A; Ringden O; Rowe JM; Saad A; Savani BN; Schouten HC; Seo S; Shah NN; Solh M; Stuart RK; Ustun C; Woolfrey AE; Yared JA; Alyea EP; Kalaycio ME; Popat U; Sobecks RM; Saber W
Blood Adv; 2018 Nov; 2(21):2922-2936. PubMed ID: 30396912
[TBL] [Abstract][Full Text] [Related]
43. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.
Bokhari SW; Watson L; Nagra S; Cook M; Byrne JL; Craddock C; Russell NH
Bone Marrow Transplant; 2012 Apr; 47(4):528-34. PubMed ID: 21743502
[TBL] [Abstract][Full Text] [Related]
44. Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States.
Hong S; Brazauskas R; Hebert KM; Ganguly S; Abdel-Azim H; Diaz MA; Beattie S; Ciurea SO; Szwajcer D; Badawy SM; Gratwohl AA; LeMaistre C; Aljurf MDSM; Olsson RF; Bhatt NS; Farhadfar N; Yared JA; Yoshimi A; Seo S; Gergis U; Beitinjaneh AM; Sharma A; Lazarus H; Law J; Ulrickson M; Hashem H; Schoemans H; Cerny J; Rizzieri D; Savani BN; Kamble RT; Shaw BE; Khera N; Wood WA; Hashmi S; Hahn T; Lee SJ; Rizzo JD; Majhail NS; Saber W
Cancer; 2021 Feb; 127(4):609-618. PubMed ID: 33085090
[TBL] [Abstract][Full Text] [Related]
45. Adjusting DLCO for Hb and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index.
Coffey DG; Pollyea DA; Myint H; Smith C; Gutman JA
Bone Marrow Transplant; 2013 Sep; 48(9):1253-6. PubMed ID: 23503530
[TBL] [Abstract][Full Text] [Related]
46. The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT.
Shouval R; Fein JA; Cho C; Avecilla ST; Ruiz J; Tomas AA; Sanchez-Escamilla M; Flores NC; Yáñez L; Barker JN; Dahi P; Giralt SA; Geyer AI; Gyurkocza B; Jakubowski AA; Lin RJ; O'Reilly RJ; Papadopoulos EB; Politikos I; Ponce DM; Sauter CS; Scordo M; Shaffer B; Shah GL; Sullivan JP; Tamari R; van den Brink MRM; Young JW; Nagler A; Devlin S; Shimoni A; Perales MA
Blood Adv; 2022 Mar; 6(5):1525-1535. PubMed ID: 34507354
[TBL] [Abstract][Full Text] [Related]
47. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.
Maruyama D; Fukuda T; Kato R; Yamasaki S; Usui E; Morita-Hoshi Y; Kim SW; Mori S; Heike Y; Makimoto A; Tajima K; Tanosaki R; Tobinai K; Takaue Y
Biol Blood Marrow Transplant; 2007 Aug; 13(8):932-41. PubMed ID: 17640597
[TBL] [Abstract][Full Text] [Related]
48. Relative Telomere Length before Hematopoietic Cell Transplantation and Outcome after Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia.
Wang Y; Wang T; Dagnall C; Haagenson M; Spellman SR; Hicks B; Jones K; Lee SJ; Savage SA; Gadalla SM
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1054-1058. PubMed ID: 28389255
[TBL] [Abstract][Full Text] [Related]
49. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.
Smith SM; Godfrey J; Ahn KW; DiGilio A; Ahmed S; Agrawal V; Bachanova V; Bacher U; Bashey A; Bolaños-Meade J; Cairo M; Chen A; Chhabra S; Copelan E; Dahi PB; Aljurf M; Farooq U; Ganguly S; Hertzberg M; Holmberg L; Inwards D; Kanate AS; Karmali R; Kenkre VP; Kharfan-Dabaja MA; Klein A; Lazarus HM; Mei M; Mussetti A; Nishihori T; Ramakrishnan Geethakumari P; Saad A; Savani BN; Schouten HC; Shah N; Urbano-Ispizua A; Vij R; Vose J; Sureda A; Hamadani M
Cancer; 2018 Jun; 124(12):2541-2551. PubMed ID: 29645093
[TBL] [Abstract][Full Text] [Related]
50. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database.
Majhail NS; Mau LW; Denzen EM; Arneson TJ
Bone Marrow Transplant; 2013 Feb; 48(2):294-300. PubMed ID: 22773126
[TBL] [Abstract][Full Text] [Related]
51. Patient age and donor HLA matching can stratify allogeneic hematopoietic cell transplantation patients into prognostic groups.
Garcia-Horton A; Cyriac SL; Gedde-Dahl T; Floisand Y; Remberger M; Mattsson J; Michelis FV
Eur J Haematol; 2022 Dec; 109(6):672-679. PubMed ID: 36028979
[TBL] [Abstract][Full Text] [Related]
52. Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study.
Sengsayadeth S; Labopin M; Boumendil A; Finke J; Ganser A; Stelljes M; Ehninger G; Beelen D; Niederwieser D; Blaise D; Dreger P; Mufti G; Chevallier P; Mailhol A; Gatwood KS; Gorin N; Esteve J; Ciceri F; Baron F; Schmid C; Giebel S; Mohty M; Savani BN; Nagler A
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1406-1414. PubMed ID: 29678639
[TBL] [Abstract][Full Text] [Related]
53. Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902).
Wood WA; Le-Rademacher J; Syrjala KL; Jim H; Jacobsen PB; Knight JM; Abidi MH; Wingard JR; Majhail NS; Geller NL; Rizzo JD; Fei M; Wu J; Horowitz MM; Lee SJ
Cancer; 2016 Jan; 122(1):91-8. PubMed ID: 26439325
[TBL] [Abstract][Full Text] [Related]
54. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
[TBL] [Abstract][Full Text] [Related]
55. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting.
Guru Murthy GS; Hari PN; Szabo A; Pasquini M; Narra R; Khan M; Abedin S; Chhabra S; Dhakal B; D'Souza A; Drobyski WR; Rizzo JD; Runaas L; Shah NN; Shaw B; Saber W; Fenske T; Hamadani M
Biol Blood Marrow Transplant; 2019 Apr; 25(4):827-833. PubMed ID: 30572109
[TBL] [Abstract][Full Text] [Related]
56. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.
Hamadani M; Saber W; Ahn KW; Carreras J; Cairo MS; Fenske TS; Gale RP; Gibson J; Hale GA; Hari PN; Hsu JW; Inwards DJ; Kamble RT; Klein A; Maharaj D; Marks DI; Rizzieri DA; Savani BN; Schouten HC; Waller EK; Wirk B; Laport GG; Montoto S; Maloney DG; Lazarus HM
Biol Blood Marrow Transplant; 2013 May; 19(5):746-53. PubMed ID: 23380340
[TBL] [Abstract][Full Text] [Related]
57. Prognostic Value of the Hematopoietic Cell Transplantation Comorbidity Index for Patients Undergoing Reduced-Intensity Conditioning Cord Blood Transplantation.
Salit RB; Oliver DC; Delaney C; Sorror ML; Milano F
Biol Blood Marrow Transplant; 2017 Apr; 23(4):654-658. PubMed ID: 28189904
[TBL] [Abstract][Full Text] [Related]
58. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome.
Kongtim P; Parmar S; Milton DR; Perez JMR; Rondon G; Chen J; Chilkulwar AR; Al-Atrash G; Alousi A; Andersson BS; Im JS; Hosing CM; Bashir Q; Khouri I; Kebriaei P; Oran B; Popat U; Champlin R; Ciurea SO
Bone Marrow Transplant; 2019 Jun; 54(6):839-848. PubMed ID: 30258129
[TBL] [Abstract][Full Text] [Related]
59. Hematopoietic cell transplantation for mantle cell lymphoma: predictive value of pretransplant positron emission tomography/computed tomography and bone marrow evaluations for outcomes.
Magnusson E; Cao Q; Linden MA; Frolich J; Anand V; Burns LJ; Bachanova V
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):114-21. PubMed ID: 24388482
[TBL] [Abstract][Full Text] [Related]
60. The Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation.
Shibasaki Y; Suwabe T; Katagiri T; Tanaka T; Kobayashi H; Fuse K; Ushiki T; Sato N; Yano T; Kuroha T; Hashimoto S; Narita M; Furukawa T; Sone H; Masuko M
Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28871665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
